Catalog Product Name CAS Number
BADC-00607 DXD 1599440-33-1
DXD, an Exatecan derivative for ADC, is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 μM. It can be used as a payload for antibody-conjugated drug ADCs targeting HER2. Inquiry
BADC-00841 SN-38 86639-52-3
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. Inquiry
BADC-00044 Camptothecin 7689-03-4
Camptothecin (CPT) is a potent DNA enzyme topoisomerase I (topo I) inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231. Camptothecin is extratced from the bark... Inquiry
BADC-00667 MAC glucuronide α-hydroxy lactone-linked SN-38 2246380-70-9
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker. MAC glucuronide α-hydroxy lactone-linked ... Inquiry
BADC-00666 MAC glucuronide phenol-linked SN-38 2246380-69-6
MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across... Inquiry
BADC-00854 Mc-VC-PAB-SN38 1801838-28-7
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). Inquiry
BADC-00847 CL2-SN-38 1036969-20-6
CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 and a maleimidocaproyl linker. Inquiry

Camptothecins (CPTs) are a quinoline alkaloid isolated from camptothecaacuminata decne. As a natural inhibitor of topoisomerase I, Camptothecins have good therapeutic effects on malignant tumors (eg, liver cancer, breast cancer, lung cancer and ovarian cancer), viruses and skin diseases due to the cytotoxic activities. To increase the water solubility, targeting effect and antitumor activities of Camptothecins, researchers usually modified Camptothecin’s structure by introducing polar groups, hydrophilic polymer carriers or targeted molecules at the active sites. In addition, drug molecules can be delivered to specific cells by introducing a drug loading system with targeting function and using the specificity and targeting of the transmission system to realize active and passive targeting of tumor cells.

Chemical structure

The structure of Camptothecins (CPTs) includes four hexatomic rings (two quinoline rings, one pyridone ring and one α-hydroxylactone ring with S-configuration chiral carbon) and one five-membered ring (pyrrole ring). The S-configuration chiral carbon, α-hydroxylactone and hydropyridinone are essential activity structures of Camptothecins. Most of the structural modifications of Camptothecins are concentrated in two quinoline rings and α-hydroxylactone ring. The research shown that most derivatives have good inhibitory effects on tumor cell proliferation. For example, when -NO2 group was introduced into the specific carbon atom of Camptothecins, the 9-nitrocamptothecin derivative obtained was water-insoluble, which had excellent therapeutic effect on advanced pancreatic cancer.

Mechanism of action

In the S phase of tumor cell DNA replication, Camptothecins (CPTs) inhibits DNA synthesis and induces apoptosis by inhibiting the activities of topoisomerase I. When Camptothecins bonding with topoisomerase I-DNA to form a ternary complex, it can improve the stability of topo I -DNA complex. So, DNA strand breaks cannot be reconnected to prevent DNA replication and RNA synthesis. It has no effect on G0 phase cells and slight lethality on G1, G2 and M phase cells. Furthermore, Camptothecins can destroy DNA structure directly and has no cross resistance with common antitumor drugs.


Research have shown that Camptothecins and its derivatives have inhibitory effect on HepG2 cells and can induce apoptosis. It has therapeutic effect on lung cancer, esophageal cancer, lymphosarcoma, bladder cancer, cylindric adenocarcinoma, leukemia, malignant hydatidiform mole and choriocarcinoma. In the treatment of gastric cancer, colon cancer and rectal cancer, the symptoms of patients were improved after 15-30 days, such as increased appetite, weight gain, tumor or focal lesions of barium meal examination reduction. Furthermore, DNA topoisomerase I is very active in HIV replication, and low dose Camptothecins can block the replication of HIV-1 in infected cells (acute and chronic). Recent studies have shown that Camptothecins inhibits HIV replication of patients with acute HIV infection, reaching 89%-93%. It is a natural drug for the treatment of AIDS.


  1. Das, B.; et al. Camptothecins: some recent chemical studies. Natural Product Communications, 2006, 1(3): 255-63.
  2. Saleem, A.; et al. Mechanisms of resistance to camptothecins. Camptothecins: unfolding their anticancer potential, 2000, 46-55.
* Only for research. Not suitable for any diagnostic or therapeutic use.

Send Inquiry

Verification code
Inquiry Basket